about
Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover studyA comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferationTolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trialsSafety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjectsGiving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjectsNetazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.Survey of users of TOPS, an internet-based system to prevent healthy subjects from over-volunteering for clinical trials.The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.Potential clinical indications for a CCK2 receptor antagonist.Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.Biological therapies: a long way on from JennerA new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma.Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin.Are published normal ranges of serum testosterone too high? Results of a cross-sectional survey of serum testosterone and luteinizing hormone in healthy men.Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge.Regulatory experience of TOPS: an internet-based system to prevent healthy subjects from over-volunteering for UK clinical trials.Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects.Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses.A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.Effect of Inhaled Interferon Beta-1a on Carbon Monoxide Transfer Factor in Healthy Volunteers.Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects.Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
P50
Q24608623-06B2B92D-06C7-4A4A-A187-61179FE8BDFCQ28568444-722A9C82-9FFA-45B9-BF61-E8054E11A2B2Q34571030-F1610EE8-C08A-4422-86BC-3911C2815E15Q35009459-56EBD8B9-944B-471C-A0C3-57518E2EDD62Q35557414-36AD537F-1167-4910-A05F-981ABAC3D532Q36028576-E2DE7872-25E1-401F-B9BD-CF9AD03665B7Q36830103-9B4D8159-0ADD-4053-892C-B9722D7A70D3Q37064733-5AC386AA-BBAC-4262-A359-EA4FEA763C95Q37369296-6A4CEAB7-7761-47F8-B15B-48D7A05312B7Q37369301-E3AB3E51-C7F5-44D5-A2D3-61F5645AF6B4Q38112590-12CA84F1-A050-46AE-AE47-451B978BE614Q38967224-AD8120AE-5E86-44EE-8A37-D97B72B11B42Q38973512-A5301033-5E3E-48FE-8FE8-7FF696299E52Q39669592-E9A5018F-A353-43EA-BAF9-47B08C2E878EQ41458940-BDE5C4B8-8243-4034-A83A-4F2B9DF52EDBQ41610309-BE8F9E81-2A59-4A1E-ADC4-FD099A4611FEQ41883888-863AE375-DF49-44F5-ACD4-939E34EEEF98Q42613684-C6210387-7409-4F94-B2F3-8F07BA9F32EEQ42718034-37C27AC0-B8B8-406A-B444-037C428C1075Q43166910-87F984D1-1A5D-43B4-83E2-630E3B00A3BEQ43829880-A2003F12-07CF-419C-A973-68A23422E24DQ44080548-C66BCF2A-435B-44CB-BF82-4692D7FA2754Q44244468-43CC1869-9038-40B5-BF7F-09B3BF3A9AC9Q45100357-5608210C-B267-44BA-B867-CD8ADB81DEE8Q46051440-0448D97D-F317-41AA-BF89-96FE15F8062AQ46283673-22901DC3-3A68-49B2-8484-C2EA4506AED5Q46739778-D2301CD9-1EA4-4DE5-B324-6FFC553DF3FFQ46787784-134541DD-17FB-4A42-A601-F08BBD840F79Q47979781-853DA842-F2F8-4FF3-8233-6C2D3CFD6211Q48263186-51FF2F11-67B6-455E-82A4-FDA3C9BEE607Q48298084-BB30FB4D-FA11-42FC-B5A0-0ED92148E4ECQ48339316-ACF86BBF-E8D1-43E7-9663-DAC45D2A2BDBQ49068827-5E6DF7BC-7C1F-4A51-9CB4-8781D1548216Q51221364-56E3F440-4B4B-45A5-96A3-05E6336D2F1BQ51271053-C2BAD972-738C-4314-BC59-54A4BDA17164Q51308018-CBEC0144-9D7A-4C27-8DE5-A114942AC123Q51350256-94CC8FD1-7492-428D-9D65-EE9B00941BBAQ51563173-70C59599-A595-4A81-92D5-A51273A59457Q51683877-7E517438-0856-49F8-992E-BAD4DBD1E4F3Q51691696-0C0530A7-E05F-40D7-A027-5A403053EB83
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Malcolm Boyce
@ast
Malcolm Boyce
@en
Malcolm Boyce
@es
Malcolm Boyce
@nl
Malcolm Boyce
@sl
type
label
Malcolm Boyce
@ast
Malcolm Boyce
@en
Malcolm Boyce
@es
Malcolm Boyce
@nl
Malcolm Boyce
@sl
altLabel
Malcolm James Boyce
@en
prefLabel
Malcolm Boyce
@ast
Malcolm Boyce
@en
Malcolm Boyce
@es
Malcolm Boyce
@nl
Malcolm Boyce
@sl
P106
P1153
9274129000
P21
P31
P496
0000-0001-8807-612X
P569
2000-01-01T00:00:00Z